Back to top
more

Repare Therapeutics (RPTX)

(Delayed Data from NSDQ)

$3.59 USD

3.59
70,883

+0.10 (2.87%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $3.58 -0.01 (-0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.86% and 13.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

by Zacks Equity Research

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Repare Therapeutics (RPTX) delivered earnings and revenue surprises of 3.53% and 73.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

by Zacks Equity Research

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.

Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates

by Zacks Equity Research

Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.

Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

by Zacks Equity Research

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

by Zacks Equity Research

Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

by Zacks Equity Research

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 66.27% and 315.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -4.69% and 0.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 20% and 8.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%

by Zacks Equity Research

The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?